Antiphospholipid Antibody Induced by Nivolumab
Joint Authors
Aburahma, Ahmed
Aljariri Alhesan, Nour
Elounais, Farah
Abu Sitta, Emad
Source
Issue
Vol. 2018, Issue 2018 (31 Dec. 2018), pp.1-3, 3 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2018-01-11
Country of Publication
Egypt
No. of Pages
3
Main Subjects
Abstract EN
Nivolumab is a monoclonal antibody against the programmed death protein 1 and is used for patients with advanced melanoma.
It is associated with potentially immune-related adverse events, including disorders of the skin, GI tract, and the thyroid; these disorders were successfully treated with prednisone and infliximab.
Other immunotherapeutic agents were observed to induce the formation of antiphospholipid antibody (APA) including α-interferon and interleukin-2.
We present a case of APA development after the third dose of nivolumab in a 71-year-old male with advanced melanoma.
The APA was detected after finding a prolonged aPTT; the lupus anticoagulant assay tested positive.
The patient was treated with prednisone but, unfortunately, he expired a few days later.
American Psychological Association (APA)
Aburahma, Ahmed& Aljariri Alhesan, Nour& Elounais, Farah& Abu Sitta, Emad. 2018. Antiphospholipid Antibody Induced by Nivolumab. Case Reports in Hematology،Vol. 2018, no. 2018, pp.1-3.
https://search.emarefa.net/detail/BIM-1143792
Modern Language Association (MLA)
Aburahma, Ahmed…[et al.]. Antiphospholipid Antibody Induced by Nivolumab. Case Reports in Hematology No. 2018 (2018), pp.1-3.
https://search.emarefa.net/detail/BIM-1143792
American Medical Association (AMA)
Aburahma, Ahmed& Aljariri Alhesan, Nour& Elounais, Farah& Abu Sitta, Emad. Antiphospholipid Antibody Induced by Nivolumab. Case Reports in Hematology. 2018. Vol. 2018, no. 2018, pp.1-3.
https://search.emarefa.net/detail/BIM-1143792
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1143792
